Nutrients, Vol. 17, Pages 2189: Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Nutrients doi: 10.3390/nu17132189
Authors:
Daniel Clayton-Chubb
William W. Kemp
Ammar Majeed
Peter W. Lange
Jessica A. Fitzpatrick
Karl Vaz
John S. Lubel
Alexander D. Hodge
Joanne Ryan
John J. McNeil
Alice J. Owen
Robyn L. Woods
Stuart K. Roberts
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide. Its incidence has been increasing rapidly, alongside the growing epidemics of type 2 diabetes mellitus and overweight/obesity. Global population age has also been increasing in parallel, and predictions indicate there will be more than 2 billion persons aged over 65 by the year 2050. The interplay between MASLD and other health conditions of older persons has been a focus of recent research. In this narrative review, we aim to describe its prevalence; clinical and sociodemographic associations; and outcomes for older persons, all of which are of significant importance when considering public health messaging as well as screening and counselling individual older adults.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide. Its incidence has been increasing rapidly, alongside the growing epidemics of type 2 diabetes mellitus and overweight/obesity. Global population age has also been increasing in parallel, and predictions indicate there will be more than 2 billion persons aged over 65 by the year 2050. The interplay between MASLD and other health conditions of older persons has been a focus of recent research. In this narrative review, we aim to describe its prevalence; clinical and sociodemographic associations; and outcomes for older persons, all of which are of significant importance when considering public health messaging as well as screening and counselling individual older adults. Read More